MANUFACTURING OF PLASMID AND VECTOR AND GLP DOSE-ESCALATION TOXICOLOGY STUDIES
Full Description
Currently, the National Institute of Neurological Disorders and Stroke (NINDS), via its URGenT network,
is funding a cooperative agreement for the manufacturing of an AAV9 vector, plasmids, and GLP
dose-escalating studies as a potential therapy the severe and progressive genetic neurological disorder,
Aspartylglucosaminuria (AGU). The goals of the URGenT cooperative agreement are to manufacture the vector, plasmid, and initial GMP batch.
Grant Number: 75N95022D00021-P00003-759502300003-1
NIH Institute/Center: NIH
Principal Investigator: Amanda Burnaugh
Sign up free to get the apply link, save to pipeline, and set email alerts.
Sign up free →Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click